Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase: S0033. - Blanke,C.D.; Rankin,C.; Demetri,G.D. (J Clin Oncol, 2008)